Key result
Intrapericardial VEGF-A mRNA delivery attenuates adverse remodeling and recovers LVEF after MI in mice.
Why the study?
Clinical translation of regenerative gene therapy for cardiac repair after myocardial infarction has been limited by a lack of targeted, minimally invasive, and clinically scalable delivery strategies.
Does localized intrapericardial delivery and point-source electrotransfection of VEGF-A mRNA via an injectable bioresorbable conductive hydrogel improve cardiac function and attenuate adverse remodeling in a mouse model of myocardial infarction?
Does localized intrapericardial delivery and point-source electrotransfection of VEGF-A mRNA via an injectable bioresorbable conductive hydrogel improve cardiac function and attenuate adverse remodeling in a mouse model of myocardial infarction?
This preclinical study demonstrates a minimally invasive, bioresorbable intrapericardial hydrogel electrode platform capable of targeted in vivo mRNA electrotransfection that restores cardiac function via VEGF-A mRNA delivery after myocardial infarction in mice.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for post-MI repair; extends bioresorbable electroactive mRNA platforms but requires human validation.
Myocardial infarction (MI) causes irreversible cardiomyocyte loss and triggers inflammatory and fibrotic remodeling that promote the progression to heart failure. Although regenerative gene therapy offers a promising route to cardiac repair, clinical translation has been limited because of the lack of targeted, minimally invasive, and clinically scalable delivery strategies. Here we report an injectable, bioresorbable in situ-formed electroactive device that enables local mRNA delivery through the pericardial space, a clinically established route of access. Following administration, the formulation self-assembles into a transient conductive mRNA-carrying drape electrode over the injured heart, enabling in vivo electrotransfection, and is then bioresorbed, eliminating the need for retrieval. In animal models, the formulation was well tolerated, did not disrupt cardiac contractile activity, and enabled targeted mRNA transfer. In a mouse model of MI, localized delivery of vascular endothelial growth factor (VEGF-A) mRNA attenuated adverse remodeling, improved cardiac function (e.g., stroke volume and ejection fraction were fully recovered), and established a minimally invasive strategy for localized regenerative gene delivery to the injured heart.
No takes yet. Share an insight, caveat, or question.
Aydemir et al. (2026) studied Myocardial infarction (preclinical animal models). Injectable bioresorbable in situ-formed A5:ETE-BuSA drape electrode loaded with VEGF-A mRNA with in vivo electrotransfection vs. Vehicle drape electrode without mRNA (A5:ETE-BuSA alone) was evaluated on Recovery of cardiac function (ejection fraction and stroke volume) assessed by cardiac MRI and echocardiography. Intrapericardial delivery of VEGF-A mRNA via an injectable bioresorbable electroactive drape electrode attenuated adverse remodeling and recovered stroke volume and ejection fraction in mice after MI.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: